This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Incandela, L. Articles by Acerbi, G. Search for Related Content PubMed PubMed Citation Articles by Incandela, L. Articles by Acerbi, G. Social Bookmarking                         What's this?

Treatment of Diabetic Microangiopathy and Edema with HR (Paroven, Venoruton; 0-(ß-hydroxyethyl)-rutosides): A Prospective, Placebo-Controlled, Randomized Study

M. R. Cesarone, MD

M. T. DeSanctis, MD

G. Belcaro, MD, PhD

M. Dugall, MD

G. Acerbi, MD

This study was planned to demonstrate in a prospective, placebo-controlled, randomized study, whether HR (Paroven, Venoruton; 0-(P-hydroxyethyl)-rutosides), is effective in improving the microcirculation in subjects with diabetic microangiopathy and neuropathy. Patients with severe diabetic microangiopathy, neuropathy and edema, patients with microangiopathy, without neuropathy, and 20 healthy subjects were included. Microangiopathy was defined by laser Doppler flowmetry and capillary filtration (rate of ankle swelling (RAS)). Inclusion criteria were: increase in resting flux (RF) and RAS, a decrease in venoarteriolar response (VAR), and alterations in flux increase with temperature. The 2 groups of patients and the control group were randomized in a treatment sub-group which received HR (1 g, twice daily for 6 months); those in the placebo group received similar treatment.

Results: Groups were comparable; there were no drop-outs. There were no differences in the treatment and placebo groups at inclusion. Treatment was well tolerated; no adverse effects were reported. No variations were observed in healthy subjects at 6 months. In both groups of patients, significant decreases (P < 0.05) in RF and RAS were observed in the active treatment groups. The decrease in RAS was associated with a decrease in edema (P < 0.05) in both treatment groups. The decrease in RF and the increase in VAR were associated with a proportional decrease in RAS (P < 0.05). In patients without neuropathy, the variations in RF, VAR, and RAS were larger (P < 0.05) at 6 months. The variations in healthy subjects were limited and not significant.

Conclusion: The decrease in capillary filtration and edema with HR is associated with symptomatic improvement. The action on edema is beneficial for the evolution of neuropathy. The effects of HR on flux, RAS, and edema are important in early stages of microangiopathy to avoid progression to clinical stages.

Key Words: diabetes • diabetic microangiopathy • ulcerations • compression • edema • peripheral vascular disease

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 7, No. 1 suppl, S11-S15 (2002)
DOI: 10.1177/107424840200700104


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. Belcaro, M. Rosaria Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. O-({beta}-Hydroxyethyl)-Rutosides Systemic and Local Treatment in Chronic Venous Disease and Microangiopathy: An Independent Prospective Comparative Study Angiology, March 1, 2008; 59(1_suppl): 7S - 13S. [Abstract] [PDF]

				G. Belcaro, M. R. Cesarone, A. Ledda, M. Cacchio, I. Ruffini, A. Ricci, E. Ippolito, A. Di Renzo, M. Dugall, M. Corsi, et al. 5-Year Control and Treatment of Edema and Increased Capillary Filtration in Venous Hypertension and Diabetic Microangiopathy Using O-({beta}-Hydroxyethyl)-Rutosides: A Prospective Comparative Clinical Registry Angiology, March 1, 2008; 59(1_suppl): 14S - 20S. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, A. Di Renzo, I. Ruffini, G. Gizzi, E. Ippolito, et al. Venoruton(R) vs Daflon(R): Evaluation of Effects on Quality of Life in Chronic Venous Insufficiency Angiology, March 1, 2006; 57(2): 131 - 138. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, M. Dugall, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides; (Venoruton(R)): Rapid Relief of Signs/Symptoms in Chronic Venous Insufficiency and Microangiopathy: A Prospective, Controlled Study Angiology, March 1, 2005; 56(2): 165 - 172. [Abstract] [PDF]

				M. R. Cesarone, G. Belcaro, L. Pellegrini, A. Ledda, A. Di Renzo, G. Vinciguerra, A. Ricci, G. Gizzi, E. Ippolito, F. Fano, et al. HR, 0-(Beta-Hydroxyethyl)-Rutosides, in Comparison with Diosmin+Hesperidin in Chronic Venous Insufficiency and Venous Microangiopathy: An Independent, Prospective, Comparative Registry Study Angiology, January 1, 2005; 56(1): 1 - 8. [Abstract] [PDF]